• 1. Evaluate ACC/AHA guidelines and strategies for integration into cardiovascular prevention practice. 
• 2. Apply modernized risk prediction models, including PREVENT, to improve accuracy in identifying at-risk patients. 
• 3. Differentiate between statins and novel lipid-lowering therapies to optimize individualized treatment plans. 
• 4. Integrate lifestyle medicine into patient counseling and long-term management. 

Session 2: Cardiomyopathies and Pulmonary Hypertension – Early Detection and Treatment
After this session, participants should be able to: 

• 1. Describe emerging therapeutic options for Group II pulmonary hypertension and their clinical implications. 
• 2. Utilize advanced imaging modalities to aid in the early detection of myocarditis and pericarditis. 
• 3. Recognize clinical signs of cardiac amyloidosis and apply evidence-based therapeutic approaches. 
• 4. Implement strategies to prevent and manage cancer therapy–related cardiotoxicity in collaboration with oncology teams. 

Session 3: Interventional and Structural Heart Disease
After this session, participants should be able to: 

• 1. Describe the medical risk and complications associated with obesity 
• 2. Utilize various approaches to managing obesity (lifestyle modifications, medical management, and surgical interventions) 
• 3. Recognize the feedback control mechanism for bodyweight and leptin 
• 4. Integrate the use of GLP-1’s into practice
• 5. Apply current evidence and algorithms in the recognition and management of cardiogenic shock. 
• 6. Assess indications, risks, and outcomes for transcatheter tricuspid valve repair. 
• 7. Evaluate updated criteria for early TAVR and determine appropriate patient selection. 
• 8. Identify and address disparities in the diagnosis and treatment of ischemic heart disease in women. 

Session 4: Cardiac Arrhythmias and Devices
After this session, participants should be able to: 

• 1. Determine appropriate anticoagulation strategies for patients with device-detected atrial fibrillation. 
• 2. Assess the clinical utility and patient selection criteria for dual-chamber leadless pacemakers. 
• 3. Compare left bundle branch pacing with traditional pacing modalities to inform device therapy decisions.